Antibody Binding vs. Aptamer Binding
The immune system has developed very effective screening methods for eliminating antibodies that bind even weakly to self targets such as serum albumin and IgG. Aptamer selection is done outside the body, on the bench which provides many advantages but implicit immune tolerance in selection is not one of them.
Counter Selection
Counter selection against off-targets has been the only way to produce aptamers that will not bind to other targets in bodily fluids. SELEX is based on the use of 1E15 sequences derived from 1.2E24 possible sequences. This means that every selection is based on a new set of sequences. It has not been possible to test the same starting set of sequences on different targets.
Counter selection is very effective against those sequences that bind tightly to the off target. It is not effective in removing those sequences that bind weakly. To be clear, counter selection is not as effective or as thorough as immune tolerance.
Does this really matter? Unfortunately, yes. Abundant proteins like serum albumin are present in blood at an average concentration of 600 uM. If we are trying to detect targets at much lower concentrations even weak counter-binding will result in saturation of aptamer binding to serum albumin.
Our Solution
NeoVentures has overcome this problem with our new Neomer aptamer selection method. The method involves application of an average of 1,000 copies of each of the same 4.29 billion sequences to every target. This means that we can identify all the sequences that bind even weakly to abundant proteins and remove them as candidates for your target. In essence we have created an in-silico alternative to avoiding self-recognition. This is a game changing innovation which will definitely lead to better performance of aptamers in diagnostic applications. Read more about Neomer in our blog.
To learn more about what this means for your ability to use aptamers to overcome problems in your diagnostic portfolio, contact our team today.
Follow us on LinkedIn to get notified every time we release new information on Neomer.
El Dr. Gregory Penner recibió una formación académica que combinaba teoría muy práctica de mejoramiento de plantas con biología molecular. Ha utilizado esta combinación de biología y matemáticas para desarrollar y liderar primero un equipo de investigación en biotecnología de cereales con el gobierno de Canadá y posteriormente como líder de investigación global en Monsanto Inc. Ha sido un líder de pensamiento en el desarrollo de aptámeros a nivel mundial durante los últimos veinte años como CEO y Presidente de NeoVentures. Ha llevado a esta empresa a una estabilidad financiera sin inversión externa con un enfoque integrado en el descubrimiento y comercialización de aptámeros. En 2015, cofundó una segunda empresa, NeoNeuro en París, Francia, centrada en un enfoque innovador para identificar Aptamarcadores para enfermedades complejas.
Conéctate con el Dr. Penner en LinkedIn Para actualizaciones de la compañía, sigue: NeoVentures.
Spanish 
English 
French